Alfadil Haroon: Bleeding Outcomes in Congenital Versus Acquired FXIII Deficiency
Alfadil Haroon, Assistant Consultant of Hematology at King Faisal Specialist Hospital and Research Centre, Assistant Professor at Alfaisal University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in HemaSphere, adding:
“Factor XIII Deficiency: Congenital versus Acquired
Study overview
- 25 patients (52 percent congenital, 48 percent acquired)
- Median age: 35 years
Congenital FXIII deficiency:
- Diagnosed early (younger patients)
- Very low FXIII levels
- Managed with long-term prophylaxis
- Lower bleeding risk (46 percent)
Acquired FXIII deficiency:
- Occurs later (median approximately 60 years)
- Strongly linked to malignancy (92 percent)
- Higher FXIII levels than congenital
- Severe bleeding in 92 percent
Bleeding Patterns:
- Acquired FXIIID – more severe bleeding
- GI bleeding: 41.6 percent
- Muscle/joint: 33.3 percent
Congenital FXIIID
- Mucosal bleeding only in this group
- CNS bleeding similar in both groups (approximately 15–16 percent)
Key Biomarker Insight
- FXIII level predicts bleeding only moderately
- AUC equals 0.70
- Best cutoff: 0.13 IU/mL
Management Highlights
Congenital: Long-term FXIII replacement (92 percent)
Acquired: Treat underlying disease (especially malignancy), FXIII plus antifibrinolytics for bleeding
Take-Home Messages
- Congenital is not Acquired – completely different diseases
- Acquired FXIIID equals high-risk bleeding disorder
- FXIII level alone is not enough for risk stratification
Clinical Pearl
Patients with acquired FXIII deficiency bleed more despite higher factor levels – highlighting the importance of etiology over numbers.”
Title: Distinct Clinical Profiles and Bleeding Severity in Congenital and Acquired Factor XIII Deficiency: A Single-Center Experience
Authors: Alfadil Haroon, Tusneem Alhassan, Hazzaa Alzahrani

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments